Premium
Opioid Use Disorder in Pregnancy
Author(s) -
Roper Van,
Cox Kim J.
Publication year - 2017
Publication title -
journal of midwifery and women's health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.543
H-Index - 62
eISSN - 1542-2011
pISSN - 1526-9523
DOI - 10.1111/jmwh.12619
Subject(s) - opioid use disorder , buprenorphine , medicine , pregnancy , population , primary care , opiate substitution treatment , opioid , adverse effect , nursing , family medicine , intensive care medicine , psychiatry , environmental health , pharmacology , receptor , biology , genetics
Opioid use disorder (OUD) in pregnancy has increased significantly in the past 10 years. Women with OUD may often be undertreated or untreated because of limited accessibility to treatment, particularly in rural areas. Because detoxification is not recommended during pregnancy due to the potential for adverse outcomes in the fetus and a high risk of relapse for the woman, more primary care providers need to be well versed in opioid‐assisted therapy. In addition, recent changes in Food and Drug Administration regulations now allow nurse practitioners and physician assistants with specialized training to provide buprenorphine treatment for pregnant women with OUD in primary care settings. The purpose of this article is to provide information and guidance for clinicians working with and treating this population.